Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$87.71
-$0.34(-0.84%)
At close: 4:00 PM EST
$87.71
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$36.65 - $130.05
Previous CloseN/A
Volume48.51K
Average Volume (3M)1.06M
Market Cap
$9.79B
Enterprise Value$7.33B
Total Cash (Recent Filing)$650.93M
Total Debt (Recent Filing)$80.47M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Jul 31, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,257,590
10 Day Avg. Volume1,491,867
30 Day Avg. Volume1,059,219
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue142.45
Enterprise Value/Gross Profit142.45
Enterprise Value/Ebitda-23.95
Forecast
1Y Price Target
$127.67Price Target Upside45.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.47
Revenue Forecast (FY)$84.46M
Bulls Say, Bears Say
Bulls Say
Clinical Execution / Trial EnrollmentFinishing BROADEN2 enrollment early accelerates the timetable to topline data by year-end 2026 and supports moving to Phase 3 by mid-2027. Faster enrollment signals strong patient/provider demand and reduces development timeline risk, improving the odds of timely milestones and partner interest.
Balance Sheet StrengthVery low debt and a large equity base provide financial flexibility to fund multi-year clinical programs, pursue partnerships, or access capital markets without heavy interest burdens. This structural balance sheet strength reduces insolvency risk and preserves strategic optionality during development.
Revenue Growth From CollaborationsMeaningful year-over-year revenue growth for a clinical-stage biotech reflects expanding collaboration/licensing receipts and validation from partners. Growing non-product revenue helps offset some R&D cash needs, diversifies funding sources, and signals external confidence in the pipeline.
Bears Say
High Cash BurnSustained negative operating and free cash flow at roughly quarter-billion dollar annual rates creates persistent financing needs. Over the medium term this elevates dilution and refinancing risk, constrains strategic optionality, and makes program continuity reliant on external capital or milestone payments.
Large Net Losses / Negative ProfitabilitySubstantial and widening net losses indicate the company is not generating operational profits and cannot self-fund commercialization. Negative margins and returns imply prolonged reliance on partners and capital markets; sustained losses also pressure long-term value creation for shareholders.
Senior Management TransitionLoss of the COO creates medium-term operational uncertainty during a critical development and scaling window. Although an advisory transition mitigates immediate disruption, prolonged leadership gaps can slow trial operations, commercialization planning, and cross-functional coordination needed to execute multiple late-stage programs.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $36.65 and its highest was $130.05 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $9.79B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 20 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.171.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.73.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 82,257,590 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -0.54%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.67 (45.56% Upside)
$127.67 (45.56% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 104.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.39%
12-Months-Change
Fundamentals
Return on Equity
-25.02%
Trailing 12-Months
Asset Growth
81.75%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$127.67
▲(45.56% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
12.06% Insiders
36.88% Mutual Funds
0.03% Other Institutional Investors
36.73% Public Companies and
Individual Investors